Actuate Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations

Market Cap $37.87M
PE -1
Debt $NaN
Cash $13.52M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$27.18M
EBIT	-$25.08M
ROE	-507%
ROA	-176%
Equity	$5.36M
Growth Stability	1
PE	-1.39
PB	7.07
Price/Cash	0.36
Earnings Growth YoY	8%
Earnings Growth QoQ	-9%

Market Cap	$37.87M
Assets	$14.26M
Cash	$13.52M
Shares Outstanding	4.65M
Working Capital	5.77M
Current Ratio	1.68
Shares Growth 3y	14%
Equity Growth QoQ	-105%
Equity Growth YoY	-106%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).

SEC Filings

Direct access to Actuate Therapeutics, Inc. (ACTU) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does Actuate Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Actuate Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Actuate Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Actuate Therapeutics, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	TTM
Net Margins	-
ROA	-176%
ROE	-507%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	TTM
Debt over FCF	-
Debt over Equity	-
Growth Stability	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	CAGR 5Y
Revenue YoY growth	-
Earnings YoY growth	-
Equity YoY growth	-
FCF YoY growth	-